




# **Targeted Multidrug Resistant Organisms in Michigan**

---



**Sara McNamara, MPH, MT(ASCP), CIC**  
**Surveillance for Healthcare-Associated and  
Resistant Pathogens Unit**  
**Michigan Department of Health and Human  
Services**

# Multidrug-Resistant Organisms




# Targeted Multidrug-Resistant Organisms



## What do they have in common?

- Opportunistic pathogens that can **colonize** multiple mucosal and/or skin surfaces
- Cause a **variety of infections**, most commonly urinary tract, wound, and bloodstream infections, and pneumonia
- Often **resistant** to some antibiotics/antifungals often used for treatment of infection
- In **healthcare settings**, transmitted via **direct and indirect contact** with infected or colonized individuals or **contaminated healthcare environment**
- Are **emerging in prevalence** in the region


# Colonization Drives MDRO Spread and Precedes Infection



Shedding of MDROs from colonized individuals leads to contamination of HCP hands and clothing and the surrounding healthcare environment



Colonization confers a 2-10 fold higher risk of infection with the colonizing organism



For every individual identified with an MDRO infection, there are some multiplier more who are colonized






# *Candida auris*


*An emerging yeast MDRO*

# *Candida auris* Cases in Michigan




*\*Preliminary Data Available as of 1/24/23*

# Healthcare Facility Type at Case Detection



*\*Preliminary Data Available as of 1/24/23*


# Local Health Jurisdiction of Healthcare Facility



\*Preliminary Data Available as of 1/24/23




# *Candida auris* Outbreaks<sup>‡</sup> Detected



<sup>‡</sup> Outbreak defined as  $\geq 2$  epi-linked cases

<sup>\*</sup> Preliminary Data Available as of 1/16/23, Subject to Change

# Specimen Source of MI *Candida auris* Isolates



*\*Preliminary Data Available as of 1/24/23*

# Clinical Isolate Antifungal Resistance


## Azoles



## Echinocandins



## Polyenes



\* Epi-linked cases from 1 outbreak

\*Preliminary Data Available as of 1/24/23

# Demographics & Common Risk Factors



## Demographics

Age, Median 62 yrs  
(range 18->89)

Male Gender (50%)

Black/AA (51%)

Caucasian (19%)

Asian (1%)

Other (5%)

Unknown (23%)



## Indwelling devices

Recent Mechanical  
Ventilation (68%)

Tracheostomy (61%)

PEG tube (66%)

CVC/PICC (38%)

Urinary Cath (43%)



## Wounds

Chronic non-  
healing or surgical  
(60%)



## HX MDROs

Hx MDROs (44%)

CRO (25%)

ESBL (20%)

MRSA (27%)

VRE (9%)



## Comorbid conditions

Chronic Lung  
Disease

Diabetes





Renal Disease

Cardiovascular  
Disease

Cancer

*\*Preliminary Data Available as of 1/16/23, Subject to Change*

# Multiple Healthcare Exposures are Common

Healthcare Setting				
	Acute Care Hospital	Long-term Acute Care Hospital	Skilled Nursing Facility w/Ventilator Care	Skilled Nursing Facility
At Time of Detection	43%	49%	6%	1%
Exposures in Last 90 Days	98%	52%	19%	17%

*\*Preliminary Data Available as of 1/16/23, Subject to Change*



Carbapenemase-producing  
Enterobacteriales



Carbapenemase-producing  
*Pseudomonas aeruginosa*



Carbapenemase-producing  
*Acinetobacter*

# Carbapenemase-Producing Organisms


*Emerging Enteric Bacteria*



# Mechanisms of Carbapenem Resistance

- Altered targets
- Avoidance of targets
- Porin loss
- Efflux pumps
- Enzymes

Carbapenemases



# Carbapenemases Vary by Organism



25-30% are CP



<5% are CP




>90% are CP

KPC, NDM, OXA-48-like, IMP, VIM

OXA-23, -24/40, 58, -235-like


# Confirmed CP-CRE Cases Reported to MDSS

## 2018-2022 YTD\*




*\*Preliminary – Data Subject to Change*

# Confirmed CP-CRE Cases Reported to MDSS 2018-2022Q3\*



\*Preliminary – Data Subject to Change

[illegible]


- 

- Contaminated Duodenoscopes
- NDM *Escherichia coli* ST648


# What Can Healthcare Facilities Do to Prevent Targeted MDROs?



**Infection Prevention  
Practices**



**Identify Colonized  
and Infected  
Individuals**



**Communicate MDRO  
Status**



**Antibiotic &  
Antifungal  
Stewardship**



# Thank You

Surveillance for Healthcare Associated and Resistant Pathogens (SHARP) Unit  
Michigan Department of Health and Human Services (MDHHS)

MDHHS-SHARP@michigan.gov  
(517) 335-8165

